Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB2YXN)

Drug Name

Ip5I Drug Info

Synonyms

diinosine-5',5"-pentaphosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P2X purinoceptor 1 (P2RX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BzATP	DM37GYA	Discovery agent	N.A.	Investigative	[2]
L-betagamma-meATP	DMTNQCE	Discovery agent	N.A.	Investigative	[2]
TNP-ATP	DMVZY0X	Discovery agent	N.A.	Investigative	[3]
MRS 2219	DM7IK68	Discovery agent	N.A.	Investigative	[4]
NF023	DMJ4GO9	Discovery agent	N.A.	Investigative	[2]
NF449	DM816Z2	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4225).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
3	Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
4	A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6.
5	Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57.